A review of berotralstat for the treatment of hereditary angioedema
- PMID: 36408587
- DOI: 10.1080/1744666X.2023.2150611
A review of berotralstat for the treatment of hereditary angioedema
Abstract
Introduction: Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) imposes a significant disease burden on patients and their families. Unpredictable episodes of angioedema, which can lead to life-threatening conditions, have a significant impact on the quality of life of the patient. The fundamental aim of the treatment of C1-INH-HAE is to ensure that patients can lead a normal life. The most effective way to do this is to prevent the onset of angioedema attacks.
Areas covered: This review gives a brief overview of the safety and efficacy of the oral kallikrein inhibitor berotralstat in C1-INH-HAE disease. It provides a comprehensive synopsis of the results of the first clinical trials with a targeted oral kallikrein inhibitor (APeX-1 [NCT02870972]; ZENITH-1 [NCT03240133]; APeX-2 [NCT03485911]; APeX-S [NCT03472040]; APeX-J [NCT03873116]), reviewing evidence on the efficacy and safety of the drug, and placing berotralstat on the spectrum of long-term prophylactic therapeutic options.
Expert opinion: The availability of the first targeted oral prophylactic drug, the kallikrein inhibitor berotralstat, in 2021, is a milestone in the treatment of patients with hereditary angioedema.
Keywords: AE-QoL; C1 inhibitor; berotralstat; bradykinin; efficacy; hereditary angioedema; kallikrein inhibitor; long-term prophylaxis; oral prophylaxis.
Similar articles
-
A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.Clin Rev Allergy Immunol. 2023 Dec;65(3):354-364. doi: 10.1007/s12016-023-08972-2. Epub 2023 Nov 2. Clin Rev Allergy Immunol. 2023. PMID: 37914894 Free PMC article. Review.
-
Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.Allergy Asthma Proc. 2021 Jul 14;42(4):274-282. doi: 10.2500/aap.2021.42.210034. Epub 2021 Jun 14. Allergy Asthma Proc. 2021. PMID: 34127176 Review.
-
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.J Allergy Clin Immunol Pract. 2024 Mar;12(3):733-743.e10. doi: 10.1016/j.jaip.2023.12.019. Epub 2023 Dec 18. J Allergy Clin Immunol Pract. 2024. PMID: 38122865 Clinical Trial.
-
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.Allergy. 2021 Jun;76(6):1789-1799. doi: 10.1111/all.14670. Epub 2020 Dec 23. Allergy. 2021. PMID: 33247955 Free PMC article. Clinical Trial.
-
Interventions for the long-term prevention of hereditary angioedema attacks.Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. Cochrane Database Syst Rev. 2022. PMID: 36326435 Free PMC article. Review.
Cited by
-
StackER: a novel SMILES-based stacked approach for the accelerated and efficient discovery of ERα and ERβ antagonists.Sci Rep. 2023 Dec 27;13(1):22994. doi: 10.1038/s41598-023-50393-w. Sci Rep. 2023. PMID: 38151513 Free PMC article.
-
Pyrazole: an emerging privileged scaffold in drug discovery.Future Med Chem. 2023 Nov;15(21):2011-2023. doi: 10.4155/fmc-2023-0207. Epub 2023 Nov 7. Future Med Chem. 2023. PMID: 37933613 Free PMC article. Review.
-
A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain).Medicine (Baltimore). 2023 Jun 9;102(23):e33971. doi: 10.1097/MD.0000000000033971. Medicine (Baltimore). 2023. PMID: 37335648 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
